Gara Jalqabaatti › Saree Oljoo › California › Mountain View
Qorannoo klinikaalii Saree Oljoo Mountain View, CA keessatti
Qorannoo 26 Saree Oljoo f Mountain View fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Stanford Women's Cancer Center, Palo Alto · Miili 5 fagaatti
A Study of PHST001 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Stanford University School of Medicine, Palo Alto · Miili 5 fagaatti
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- El Camino Hospital, Mountain View
- Palo Alto Medical Foundation, Mountain View
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Stanford Medicine Cancer Center, Stanford · Miili 5 fagaatti
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Namoota walitti qabaa jiraSadarkaa 3
- El Camino Hospital Cancer Center ( Site 0096), Mountain View
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Namoota walitti qabaa jiraSadarkaa 1
- Stanford University Medical Center, Stanford · Miili 5 fagaatti
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Stanford University Medical Center, Stanford · Miili 5 fagaatti
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Namoota walitti qabaa jiraSadarkaa 3
- Stanford Cancer Center, Palo Alto · Miili 5 fagaatti
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto · Miili 5 fagaatti
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- Stanford Women's Cancer Center, Palo Alto · Miili 5 fagaatti
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Stanford University Hospital, Stanford · Miili 5 fagaatti
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Palo Alto · Miili 5 fagaatti
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Stanford Cancer Institute, Palo Alto · Miili 5 fagaatti
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Palo Alto Medical Foundation Research Center, Palo Alto · Miili 5 fagaatti
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · Miili 5 fagaatti
- fi 1 dabalataa
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Stanford University, Stanford · Miili 5 fagaatti
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Namoota walitti qabaa jiraSadarkaa 2/3
- Local Institution - 0358, Stanford · Miili 5 fagaatti
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Namoota walitti qabaa jiraSadarkaa 3
- Stanford Medicine Cancer Center - Stanford Women's Cancer Center, Palo Alto · Miili 5 fagaatti
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Stanford University Medical Center, Palo Alto · Miili 5 fagaatti
Magnetic Resonance Imaging of Breast Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Stanford University School of Medicine, Stanford · Miili 5 fagaatti
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Namoota walitti qabaa jiraQorannoo ilaalaa
- Stanford University School of Medicine, Stanford · Miili 5 fagaatti
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Namoota walitti qabaa jiraSadarkaa 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · Miili 5 fagaatti
- Stanford Cancer Institute Palo Alto, Palo Alto · Miili 5 fagaatti
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Stanford Cancer Institute, Stanford · Miili 5 fagaatti
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
Namoota walitti qabaa jira
- Stanford University, Stanford · Miili 5 fagaatti
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Stanford Cancer Institute, Palo Alto · Miili 5 fagaatti
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Stanford · Miili 5 fagaatti
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Houston, TXQorannoo 126
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Queens, NYQorannoo 64
- Durham, NCQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
Qorannoo biroo Mountain View keessatti
- Saree (Gosoota Hunda)Qorannoo 40
- Kansara MetastatikiiQorannoo 25
- Kansara Qara'a Non-Small CellQorannoo 21
- Leukemia Myeloidii HamaaQorannoo 19
- Kansarii OvariiQorannoo 19
- Dhibee Spektiraamii AutisimiiQorannoo 17
- Dhibee QaraQorannoo 17
- Kansarii ProstateQorannoo 15
- Cufama OnneeQorannoo 15
- AutismQorannoo 13
- Leukemia Lymphoblasticii HamaaQorannoo 13
- Kansarii ColorectalQorannoo 13
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.